Xerenex Kidney Treatment: A Game Changer for Keryx Biopharmaceuticals (KERX)

Data from the United States Renal Data System revealed that almost 600 million people have ESRD, as of 2010. According to the Centers for Disease Control and Prevention, one in 10 American adults or more than 20 million have some level of chronic kidney disease. The National Kidney and Urologic Diseases Information Clearing House (NKUDIC) indicate that the most common causes of kidney failure are diabetes and high blood pressure. There are more than 25.8 million people in United States that have diabetes, based on data from the American Diabetes Association. These figures show that the number of patients in need of ESRD treatments will grow in the years ahead. Given Zenerex’s positive safety and efficacy results, it has great potential for growth once approved by government regulators.

The shares of Keryx Biopharmaceuticals surged to more than 90 percent recently. Its market value increased to $435.6 million. The company expects to file a New Drug Application (NDA) with the FDA and a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for Zerenex in the second quarter this year.

The article Xerenex Kidney Treatment: A Game Changer for Keryx Biopharmaceuticals originally appeared on Fool.com and is written by Marivic Cabural.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.